PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39018064.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1188.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer. See related article by Grazini et al., p. 4143.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Aniline Compounds
- Acrylamides
- ErbB Receptors
- Mutation
- Drug Resistance, Neoplasm
- Lung Neoplasms
- Protein Kinase Inhibitors